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ABSTRACT 
 
C-reactive protein (CRP) is a well-known biomarker of systemic inflammation and 
cardiovascular disease.  We investigated the trends in prevalence of elevated CRP levels 
(>3.0 mg/L) in a general population of United States adults.  Data from the 27,214 subjects 
aged ≥20 years in the National Health and Nutrition Examination Survey (NHANES) 
1999-2010 were analyzed.  After adjusting for age, sex, race/ethnicity, body mass index, and 
medications for lowering blood pressure, glucose and lipids, the prevalence of elevated CRP 
decreased significantly from 36.7% in 1999-2002 to 32.0% in 2007-2010, corresponding to a 
decrease in mean CRP level from 1.92 to 1.66 mg/L (both P < 0.001).  The trend remained 
significant after additional adjustment for several traditional cardiovascular risk factors and 
use of different medications, including statins.  However, the decreasing trends were 
attenuated after additional adjustment for total bilirubin (P = 0.08 and 0.02), which increased 
from 0.62 to 0.73 mg/dL over 12 years (P < 0.001).  The decreasing trend of CRP levels is 
encouraging and may be related to the increase in total bilirubin levels.  Such trends may be 
explained in part by the increasing use of some medications such as statins that can increase 
bilirubin levels and decrease CRP levels.   
 
Key words:  C-reactive protein; epidemiology; inflammation; population; risk factors 
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C-reactive protein (CRP) is a well-known non-specific biomarker of systemic inflammation, 
which appears to be linked to the development of cardiovascular diseases (1).  Circulating 
levels are elevated in obesity, inflammation, insulin resistance, endothelial dysfunction, and 
subclinical atherosclerosis (2-4).  Prospective studies have also demonstrated that elevated 
circulating CRP levels predict deterioration of glycaemia, incident cardiovascular disease, 
and mortality (5-13).  CRP also adds prognostic information to that conveyed by the 
classical Framingham risk score for incident cardiovascular events (14).  
 
Although the recently completed Justification for the Use of statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has suggested that lowering CRP 
levels using a statin medication in asymptomatic subjects can reduce myocardial infarction, 
stroke and total mortality rate, even in subjects with elevated CRP levels but no 
hyperlipidemia (15, 16), the causal role of CRP in cardiovascular disease and related risk 
factors is still controversial (17).  Nevertheless, the clinical utility of CRP as a biomarker to 
monitor the cardiovascular risk is well-recognized.  A previous review has even suggested 
CRP level as a potential target for therapy (18).  In this regard, a recent study has suggested 
the use of age and CRP level as a simple method to identify subjects at high cardiovascular 
risk (19).  Moreover, the measurement of CRP has recently been recommended in all 
subjects with intermediate cardiovascular risk in Canada (20).  Therefore, it is important to 
investigate CRP levels at a population level to identify the proportion of subjects at high risk 
of cardiovascular disease or related outcomes according to the measurement of CRP level.  
However, to the best of our knowledge, there is no report on recent trends in the prevalence 
of elevated CRP or mean CRP levels in a national survey study.  Therefore, we investigated 
the 12-year trends in the prevalence of elevated CRP levels, as well as mean CRP level, in a 
general nationally representative non-institutionalized population of United States adults 
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during 1999-2010.   
 
MATERIALS AND METHODS 
Study subjects  
The National Health and Nutrition Examination Survey (NHANES) 1999-2010 was 
conducted by the National Center for Health Statistics of the Centers for Disease Control and 
Prevention as a continuous cross-sectional survey of the health and nutritional status of the 
civilian, non-institutionalized United States population (21).  In 1999, the survey became a 
continuous program and examined a nationally representative sample of about 5,000 persons 
each year.  Data are released for every two-year cycle and the detailed measurement 
procedures and protocols have been described on its website (21).  All participants gave 
informed consent and the study received approval from the Centers for Disease Control and 
Prevention Institutional Review Board.  In NHANES 1999-2010, there were 30,752 subjects 
aged ≥20 years who were both interviewed and examined in the mobile examination center.  
After excluding pregnant women and subjects with missing data in CRP levels and body 
mass index, there were 27,214 subjects included in the analysis.  
 
CRP measurement methods 
CRP levels were measured by latex-enhanced nephelometry with a high sensitivity using a 
Dade Behring Nephelometer II Analyzer System (Dade Behring Diagnostics Inc, Somerville, 
NJ) in NHANES 1999-2010.  The standards of the assays were prepared by Dade Behring 
Diagnostics and standardized against the WHO International Reference Preparation of CRP 
serum (21).  The measurement was performed by the Immunology Division, Department of 
Laboratory Medicine, University of Washington Medical Center, and there were no changes 
to equipment, laboratory measurement methods, or laboratory site during the 12-year period 
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(21).  The lowest reportable CRP level was approximately 0.2 mg/L (i.e. 0.02 mg/dL), 
which varied slightly with different calibrator lots.  For CRP levels below the limit of 
detection (3.0% of all subjects in NHANES 1999-2012, 3.3% in 1999-2000, 3.1% in 
2001-2002, 2.1% in 2003-2004, 2.5% in 2005-2006, 3.1% in 2007-2008, and 3.8% in 
2009-2010), a level equal to the limit of detection divided by the square root of two was 
imputed.  Two or three levels of quality controls were purchased from BioRad (Hercules, 
CA) or prepared in the laboratory.  These quality controls with CRP levels spanning from 
the borderline and high range values were run for each test series.  New controls were 
purchased or prepared in sufficient quantity to provide quality control for two years and were 
analyzed for at least 20 runs in parallel with the current controls.  Data from these quality 
controls were then used to estimate any methodological imprecision and assess the magnitude 
of any time-associated trends.  The coefficients of variation using different lots of CRP 
quality controls were all <10% in each of the 6 two-year survey periods.  Details of sample 
collection, measurement procedures, quality control, and quality assurance have been 
described elsewhere (21).  An elevated CRP level was defined as >3.0 mg/L (1).   
 
Prescription medications 
The use of prescription medications for lowering blood lipids, glucose, and blood pressure, as 
well as aspirin and clopidogrel, in the past month were assessed by questionnaires.  
Participants were asked whether they had taken or used any prescription medicine in the past 
month and showed the interviewer the medication containers and the exact name of all the 
products.  If the container was unavailable, the interviewer asked the participants to verbally 
report this information.  Details on the classification of the prescription medications can be 
found in Web Material.  A participant, who took two or more different classes of 
medications for the same therapeutic use (lowering either blood lipids, glucose, or blood 
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pressure), either as a single combination pill or several different pills, was defined as 
receiving polytherapy. 
 
Other variables of interest 
Information on race/ethnicity, education, history of cardiovascular diseases, smoking, and 
alcohol consumption was obtained from self-reported questionnaires at baseline (21, 22).  
Ever smokers were defined as subjects who had smoked ≥100 cigarettes in their lives.  
Regular alcohol drinking was defined as consumption of any type of alcoholic beverage at 
least once a week in the past year.  The estimated glomerular filtration rate (eGFR) was 
calculated using the modified prediction equation from the Modification of Diet in Renal 
Disease study (23).  Albuminuria was defined as a urinary albumin-to-creatinine ratio ≥30 
μg/mg (24).  Total bilirubin levels were measured using a Hitachi Model 917 multichannel 
analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN) in 1999-2000 with both 
commercial and in-house quality controls covering the normal and abnormal levels. The 
levels were measured using a Beckman Synchron LX20 system in 2003-2007 and a Beckman 
UniCel® DxC800 Synchron (Beckman Coulter Inc, Fullerton, CA) in 2008-2010 with both 
commercial quality controls and blind quality control specimen from NHANES.  In 
2001-2002, these levels were measured using either a Hitachi Model 917 multichannel 
analyzer or a Beckman Synchron LX20 and the reported values were adjusted by regression 
equations to allow comparison across the two methods.   Quality controls were run in each 
assay with coefficient of variation <10% in all the survey periods.  Details on the laboratory 
measurement methods of other biochemical variables can be found in Web Appendix or 
elsewhere (21). 
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Statistical analysis 
Data analysis was performed using the complex sampling function of SPSS version 20.0 
(SPSS Inc, Chicago, IL).  Data are expressed as mean or % (standard error [SE]).  
Variables with skewed distribution were expressed as geometric mean (95% confidence 
interval).  Examination sampling weights were used in all analyses to adjust for 
non-response bias and the oversampling of blacks, Mexican Americans, and the elderly to 
obtain estimates representative of the United States Census civilian non-institutionalized 
population (21).  Sampling errors were estimated using the primary sampling units and 
strata provided in the dataset.  As serum triglycerides and low-density lipoprotein (LDL) 
cholesterol were measured only in subjects who were examined in the morning session and 
had fasted for 8-24 hours, separate fasting weights were used for the analysis of these 
variables.  To obtain more reliable estimates, data from two survey cycles were combined 
together to produce estimates for each four-year period.  To analyze the trends over time, 
multiple logistic or linear regression models were used, in which survey year (1999-2000, 
2001-2002, 2003-2004, 2005-2006, 2007-2008, and 2009-2010) was included as an 
independent continuous variable.  The P values for interaction were estimated by including 
each multiplicative interaction term in the regression models in full sample after adjusting for 
the main effects of the covariates.  In a separate analysis, results were presented after 
excluding subjects with CRP levels >10 mg/L which may reflect acute inflammation (1).  A 
two-tailed P < 0.05 was considered statistically significant. 
 
RESULTS  
Table 1 shows the trends in clinical characteristics and cardiovascular risk factors from 
1999-2002 to 2007-2010.  During 1999-2010, there were significant increases in age, body 
mass index, education level, glycosylated hemoglobin, high-density lipoprotein (HDL) 
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cholesterol, eGFR, and total bilirubin, as well as the percentages of people that were 
non-smokers and regular alcohol drinkers (all adjusted P < 0.05).  There were also 
significant decreases in total cholesterol, LDL cholesterol, triglycerides, blood pressure, 
alkaline phosphatase, aspartate aminotransferase, γ-glutamyltransferase, and the prevalence 
of albuminuria (all adjusted P < 0.001).  Overall, 56.6 (SE 0.6) % of subjects reported the 
use of any prescription medication in the past month.  Among them, 76.9 (0.6) % showed 
the interviewer all the medication containers, 7.4 (0.3) % showed some, but not all, 
containers, and 15.7 (0.5) % just verbally reported this information.  As shown in Table 1, 
the use of medications for lowering blood pressure, glucose and lipids also increased 
significantly (all adjusted P < 0.001).  Among different medications, the use of 
angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), 
aldosterone receptor antagonists (ARAs), β-blockers, diuretics, metformin, thiazolidinediones, 
insulin, statins, nicotinic acid, and cholesterol adsorption inhibitor increased significantly. 
 
Table 2 shows the clinical characteristics according to different CRP levels.  As expected, 
CRP levels correlated positively with age, body mass index, glycosylated hemoglobin, total 
cholesterol, LDL cholesterol, triglycerides, systolic blood pressure, alkaline phosphatase, 
alanine aminotransferase and γ-glutamyltransferase, and correlated negatively with HDL 
cholesterol, eGFR and total bilirubin (all adjusted P < 0.01).  Subjects with elevated CRP 
levels tended to be women, less educated, smokers, and were more likely to be non-Hispanic 
Black or Mexican American (all adjusted P < 0.01).  The percentages of subjects with 
albuminuria and a history of previous diagnosis of cardiovascular disease were higher among 
subjects with elevated CRP levels (all adjusted P < 0.01).  The percentage of subjects taking 
calcium channel blockers (CCBs), β-blockers, diuretics, thiazolidinediones, insulin, statins, 
and cholesterol adsorption inhibitor was also higher among subjects with elevated CRP levels 
9 
 
(all adjusted P < 0.05) 
 
As shown in Table 3, the prevalence of elevated CRP decreased significantly from 36.7% in 
1999-2002 to 32.0% in 2007-2010 (adjusted P < 0.001).  This corresponded to a decrease in 
the mean CRP level from 1.92 to 1.66 mg/L (adjusted P < 0.001).  The decreasing trend in 
CRP levels was significant over the 8-year period in both 1999-2006 and 2003-2010 (both 
adjusted P < 0.01).  The decrease in the prevalence of elevated CRP or mean CRP level was 
significant in almost all subgroups by age (30-39, 40-49, 50-59, 60-69, 70-79, and ≥80 years), 
sex, race/ethnicity (non-Hispanic Whites, non-Hispanic Blacks, Mexican Americans, and 
others) and body mass index (<25.0, 25.0-29.9, and ≥30 kg/m2).  The change was not 
significant in those aged 20-29 years.  The decrease in CRP levels was greater in subjects 
with higher age and non-Hispanic Whites (both P for interaction < 0.05, Table 3).  In a 
separate analysis, similar trends were observed after excluding subjects with CRP levels >10 
mg/L (Web Table 1).  As shown in Web Table 2, subjects of higher age and non-Hispanic 
Whites tended to have larger increase in the use of any lipid lowering medication, especially 
statins, compared to subjects with lower age and other racial/ethnic groups (all P for 
interaction < 0.05). 
 
As shown in Table 4, the decreases in the prevalence of elevated CRP and mean CRP level 
remained significant (both P < 0.001) after adjusting for age, sex, race/ethnicity, body mass 
index, and other characteristics that changed significantly over the 12-year period, but not 
total bilirubin.  After further adjusting for total bilirubin levels, the decreasing trend in the 
prevalence of both elevated and mean CRP levels was attenuated (P = 0.076 and 0.024 
respectively), although that of mean CRP level still remained significant.  Similar trends 
were observed after excluding subjects with CRP levels >10 mg/L (Web Table 3).  
10 
 
Replacement of individual medications for lowering blood pressure, glucose, and lipids and 
their polytherapies by the use of any blood pressure, glucose, and lipid lowering medication 
in the adjustment models resulted in similar findings (Web Table 4).  As statin medications 
were the most commonly used (Table 2), we investigated whether the change in CRP or total 
bilirubin levels was related to statin use.  As shown in Web Table 5, the change in mean 
CRP level, but not total bilirubin level, was significantly larger in subjects taking statins (P 
for interaction = 0.005), although the difference in the change in prevalence of elevated CRP 
levels between subjects with and without taking statins did not reach statistical significance 
(P for interaction = 0.11).  Among subjects who did not take aspirin, clopidogrel, or any 
medication for lowering blood pressure, glucose or lipids, the trends of decreasing CRP levels 
and increasing total bilirubin levels with time remained significant (all P < 0.001, Web Table 
6). 
 
DISCUSSION 
This first report of the recent trend in CRP levels in a nationally representative population of 
United States adults shows a significant decreasing trend in CRP levels over a 12-year period.  
As CRP is a well-known non-specific biomarker of systemic inflammation, our study 
suggests that the decreasing trend could represent a significant improvement in the systemic 
inflammation status in US adults at the population level.  Therefore, if the Cardiovascular 
Inflammation Reduction Trial (25) can show a direct effect of lowering CRP levels on the 
reduction of risk for myocardial infarction, stroke and cardiovascular death, we may expect a 
future reduction in CRP or systemic inflammation-related cardiovascular complications and 
mortality. 
 
The reasons for the decreasing CRP levels with time are unclear.  As shown in this and 
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earlier studies, elevated CRP levels are associated with other cardiovascular risk factors, such 
as aging, obesity, lower education level, smoking, history of cardiovascular disease, 
hyperglycemia, elevated blood pressure, dyslipidemia, renal dysfunction and liver damage.  
A recent NHANES study has shown no significant change in body mass index or obesity 
prevalence in the United States adults from 2003-2004 to 2009-2010 (26) while other 
NHANES studies have demonstrated an improvement in the control of hypertension, diabetes, 
and hypercholesterolemia among the United States adults (27-32).  In our study, the 
decrease in the prevalence of elevated or mean CRP levels remained significant after 
adjusting for these potential confounding factors, suggesting that there may be some 
unidentified factors that may contribute to the observed decrease in CRP levels.  However, 
the decreasing trend was attenuated substantially after additional adjustment for total 
bilirubin levels.  Therefore, the decreasing trend in CRP levels over 12-year period could be 
related, at least partly, to the change in total bilirubin levels. 
 
Bilirubin has antioxidant and anti-inflammatory properties and has been identified as a 
potential biomarker for cardiovascular risk (33).  This may account for its inverse 
correlation with CRP levels (34).  In our study, we found an increasing trend of the use of 
some BP, glucose, and lipid lowering medications over 12-year period.  In this regard, 
lipid-lowering medications such as statins can reduce CRP levels (35).  Moreover, statins 
have been shown to activate heme oxygenase-1 (HO-1), which may account for their 
anti-inflammatory and anti-proliferative effects (36).  As HO-1 plays a role in the 
degradation of heme to biliverdin, carbon monoxide and ferritin, and biliverdin is converted 
to bilirubin by the enzyme biliverdin reductase (37), subjects taking statins may have higher 
total bilirubin levels (38).  Therefore, total bilirubin levels may be used as a surrogate 
marker for the statin dosage. 
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Although the decreasing trend in CRP levels was significant in subjects with and without 
taking statins, the decrease in CRP levels was larger in subjects taking statins.  Moreover, 
the percentage of subjects taking statins doubled from 8.4% to 16.0% over 12-year period.  
Therefore, the changes in total bilirubin and CRP levels could be explained at least in part by 
the increasing use of statins.  Besides statins, other drugs such as aspirin, clopidogrel, ARBs, 
and ACEIs have also been reported in some studies to have CRP lowering effect in subjects 
at high cardiovascular risk (39-42).  Their increasing uses could also contribute to the 
decreasing trend in CRP levels.  Although the decreasing trend in CRP levels did not 
attenuate after additional adjustment for the use of different medications, the significant 
decrease in CRP levels with time in the full adjustment model could be due to some residual 
confounding effects and the lack of data on the dosage of each medication.  Besides the 
increasing utilization of prescription medications, the improvement of cardiovascular risk 
profile such as education, smoking, lipids, blood pressure, renal function, and some liver 
function markers over the 12-year period may also contribute to the observed decreasing 
trend in CRP levels. 
 
NHANES 1999-2010 is a continuous survey program and this provides a good opportunity to 
study trends in the prevalence of elevated CRP levels or mean CRP levels in the recent 
12-year period from 1999-2000 to 2009-2010, especially since there were no changes to the 
equipment, laboratory measurement methods, or laboratory site (21).  Our study has the 
strengths of the large sample size, good sampling design, and good quality control of the 
NHANES, allowing us to obtain nationally representative estimates.  However, this study 
has several limitations.  We could not exclude the possibility that the observed decreasing 
trend in CRP levels could be due to a downward assay drift as assay drift was monitored 
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within each survey period, but not across different survey periods.  This could have 
exaggerated the CRP trend.  Nevertheless, the observed trend remained significant if we 
excluded the first or last four-year period, suggesting that it was unlikely to be due to large 
drift at either end of the study period.  As the sample size of this study is very large, the 
significances of the trends in some subgroups and some interaction terms could be misleading 
due to the very high power to detect very small differences/associations.  Moreover, the lack 
of data on the dosage of the prescription medications and rheumatological conditions are also 
limitations of this study.  .  
 
CONCLUSION 
There was a decreasing trend of CRP levels in the United States adults over 12-year study 
period, which may represent an improvement in systemic inflammation at the population 
level.  This decrease in CRP levels may be related to an increase in total bilirubin levels in 
the same period.  Such trends may be explained, at least in part, by increasing use of 
medications, such as statins, which have been shown to raise total bilirubin while decreasing 
CRP levels.   
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Table 1.  Trends in Clinical Characteristics in United States Adults, 1999-2010 
Characteristicsa 1999-2002  
(n = 8,074) 
2003-2006 
(n = 8,316) 
2007-2010 
(n = 10,824) 
P Value 
for Linear 
Time 
Trendb 
 % (SE) Mean (SE) 95% CI % (SE) Mean (SE) 95% CI % (SE) Mean (SE) 95% CI 
Age, years  46.1 (0.3)   46.8 (0.5)   47.1 (0.3)  0.013 
Women, % 51.0 (0.5)   50.9 (0.5)   51.3 (0.4)   0.76 
Body mass index, kg/m2   28.0 (0.1)   28.4 (0.1)   28.6 (0.1)  <0.001 
Race/ethnicity, %          0.41 
Non-Hispanic White 72.1 (1.8)   72.8 (2.1)   69.6 (2.5)   - 
Non-Hispanic Black 10.1 (1.2)   10.8 (1.3)   10.5 (1.0)   - 
Mexican American 7.0 (0.9)   7.7 (1.1)   8.4 (1.3)   - 
Others 10.9 (1.7)   8.7 (0.7)   11.5 (1.3)   - 
Education, %          0.003 
<High school 21.5 (0.8)   17.6 (0.9)   19.5 (0.9)   - 
High school diploma 25.7 (1.0)   26.0 (0.7)   24.0 (0.8)   - 
>High school 52.8 (1.4)   56.4 (1.2)   56.5 (1.4)   - 
Smoking, %          0.022 
Never  50.3 (1.3)   49.9 (0.8)   53.9 (1.2)   - 
Former 25.1 (0.9)   25.1 (0.6)   24.5 (0.7)   - 
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Current 24.5 (0.9)   25.0 (0.8)   21.6 (0.8)   - 
Regular alcohol drinking, % 34.0 (1.7)   33.9 (1.3)   36.1 (1.3)   0.018 
History of any cardiovascular 
disease, % 
7.7 (0.4)   8.7 (0.5)   8.0 (0.5)   0.25 
Glycosylated hemoglobin, %c  5.40  5.36, 5.44  5.43  5.40, 5.46  5.56  5.53, 5.59 <0.001 
Total cholesterol, mg/dLc  198.9  197.2, 200.6  195.9  194.8, 196.9  192.4  191.3, 193.5 <0.001 
HDL cholesterol, mg/dL  51.0 (0.4)   54.1 (0.3)   52.5 (0.3)  <0.001 
LDL cholesterol, mg/dLc,d  118.2  116.4, 120.0  110.5  108.9, 112.2  111.0  109.7, 112.2 <0.001 
Triglycerides, mg/dLc,d  121.2  117.6, 124.9  118.9  116.0, 121.9  109.8  107.3, 112.3 <0.001 
Systolic blood pressure, mm Hg  123.1 (0.5)   122.6 (0.3)   120.7 (0.3)  <0.001 
Diastolic blood pressure, mm 
Hg 
 72.6 (0.3)   70.7 (0.3)   70.1 (0.4)  <0.001 
eGFR, mL/min/1.73m2  86.4 (0.5)   86.1 (0.6)   88.6 (0.6)  <0.001 
Albuminuria, % 10.4 (0.5)   9.7 (0.4)   9.0 (0.4)   <0.001 
Alkaline phosphatase, U/Lc  70.1  68.7, 71.4  65.3  64.5, 66.2  64.2  63.6, 64.9 <0.001 
Alanine aminotransferase, U/Lc  22.5  22.2, 22.8  23.1  22.8, 23.4  23.0  22.7, 23.3 0.46 
Aspartate aminotransferase, 
U/Lc 
 22.9  22.6, 23.1  24.0  23.8, 24.3  24.5  24.2, 24.8 <0.001 
γ-glutamyltransferase, U/Lc  23.3  22.8, 23.8  21.4  21.0, 22.0  21.9  21.3, 22.6 <0.001 
Total bilirubin, mg/dLc  0.62  0.61, 0.63  0.70  0.69, 0.72  0.73  0.72, 0.74 <0.001 
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BP lowering medication, %           
ACEI 7.3 (0.3)   10.0 (0.5)   10.9 (0.4)   <0.001 
ARB 2.9 (0.2)   4.7 (0.4)   6.6 (0.4)   <0.001 
CCB 6.1 (0.4)   7.1 (0.4)   6.4 (0.3)   0.39 
ARA 0.4 (0.1)   0.5 (0.1)   0.7 (0.1)   0.030 
β-blockers 6.8 (0.4)   10.3 (0.5)   10.7 (0.5)   <0.001 
Diuretics 9.3 (0.7)   11.6 (0.6)   12.0 (0.6)   0.015 
Others 3.1 (0.3)   3.0 (0.2)   3.2 (0.2)   0.18 
Any of the above 21.2 (0.9)   25.4 (0.9)   27.0 (0.8)   <0.001 
Polytherapy 10.6 (0.6)   14.2 (0.7)   15.2 (0.6)   <0.001 
Glucose lowering medication, 
% 
          
Metformin 2.3 (0.2)   3.7 (0.3)   4.9 (0.3)   <0.001 
Sulfonylureas 2.8 (0.2)   3.1 (0.3)   3.1 (0.2)   0.42 
Thiazolidinediones 0.7 (0.1)   2.0 (0.2)   1.5 (0.2)   0.001 
Insulin 1.1 (0.1)   1.5 (0.1)   2.0 (0.2)   0.002 
Others 0.2 (0.0)   0.1 (0.0)   1.0 (0.1)   <0.001 
Any of the above 5.0 (0.3)   6.4 (0.3)   7.7 (0.4)   <0.001 
Polytherapy 1.8 (0.2)   3.1 (0.3)   3.6 (0.3)   <0.001 
Lipid lowering medication, %           
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Statin 8.4 (0.4)   12.5 (0.6)   16.0 (0.5)   <0.001 
Fibrate 1.0 (0.2)   1.2 (0.1)   1.5 (0.2)   0.10 
Bile acid sequestrant 0.1 (0.0)   0.3 (0.1)   0.2 (0.1)e   0.59 
Nicotinic acid 0.1 (0.0)   0.3 (0.1)   0.7 (0.1)   <0.001 
Cholesterol adsorption 
inhibitor 
0.0 (0.0)   1.2 (0.2)   2.1 (0.2)   <0.001 
Others 0.1 (0.0)e   0.0 (0.0)e   0.0 (0.0)e   0.005 
Any of the above 9.3 (0.5)   13.9 (0.7)   17.4 (0.5)   <0.001 
Polytherapy 0.4 (0.1)   1.6 (0.2)   2.9 (0.2)   <0.001 
Taking aspirin, % 0.6 (0.1)   0.5 (0.1)   1.4 (0.1)   <0.001 
Taking clopidogrel, % 0.4 (0.1)   1.5 (0.2)   1.6 (0.2)   <0.001 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARA, aldosterone receptor antagonist; ARB, angiotensin receptor blocker; CCB, 
calcium channel blocker; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; SE, standard error. 
aData are expressed as mean or % (SE).  For variables with skewed distribution, data are expressed as geometric mean (95% CI). 
bAdjusted for age, sex, race/ethnicity, and body mass index, where appropriate. 
cData were ln-transformed before analysis due to skewed distribution. 
dData were only available in a sub-sample of subjects that had fasted for 8-24 hours (n = 3,696, 3,639, and 4,858 in NHANES 1999-2002, 2003-2006, 
and 2007-2010 respectively). 
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eEstimates are unreliable due to coefficient of variation > 0.3. 
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Table 2.  Clinical Characteristics According to CRP Levels in United States Adults, 1999-2010 
Characteristicsa CRP level (mg/L) P Value 
for 
Linear 
Trendb 
 <1.0 
(n = 7,693) 
1.0-3.0 
(n = 9,258) 
>3.0 
(n = 10,263) 
 % (SE) Mean (SE) 95% CI % (SE) Mean (SE) 95% CI % (SE) Mean (SE) 95% CI 
Age, years  43.0 (0.2)   47.9 (0.3)   49.0 (0.2)  <0.001 
Women, % 45.1 (0.6)   46.6 (0.6)   60.9 (0.6)   <0.001 
Body mass index, kg/m2   25.0 (0.1)   28.1 (0.1)   31.7 (0.1)  <0.001 
Race/ethnicity, %          <0.001 
Non-Hispanic White 72.3 (1.2)   72.5 (1.4)   69.6 (1.5)   - 
Non-Hispanic Black 8.9 (0.6)   9.5 (0.7)   12.9 (0.8)   - 
Mexican American 7.0 (0.5)   7.8 (0.7)   8.2 (0.8)   - 
Others 11.7 (0.8)   10.2 (0.9)   9.3 (0.8)   - 
Education, %          <0.001 
<High school 15.9 (0.6)   19.5 (0.7)   22.7 (0.6)   - 
High school diploma 22.6 (0.6)   26.1 (0.7)   26.6 (0.6)   - 
>High school 61.5 (1.0)   54.4 (1.0)   50.6 (0.8)   - 
Smoking, %          <0.001 
Never  55.3 (0.9)   50.5 (0.8)   48.7 (0.8)   - 
Former 23.5 (0.6)   25.8 (0.7)   25.4 (0.6)   - 
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Current 21.2 (0.7)   23.7 (0.7)   25.9 (0.5)   - 
Regular alcohol drinking, % 41.4 (1.1)   35.2 (1.0)   28.2 (0.9)   0.10 
History of cardiovascular 
disease, % 
          
Congestive heart failure 1.2 (0.1)   1.8 (0.2)   3.6 (0.2)   <0.001 
Coronary heart disease 2.3 (0.2)   3.6 (0.2)   4.3 (0.2)   0.024 
Angina 1.8 (0.2)   2.4 (0.2)   3.6 (0.2)   0.11 
Heart attack 2.4 (0.2)   3.3 (0.2)   4.5 (0.2)   0.005 
Stroke 1.6 (0.2)   2.3 (0.2)   3.8 (0.3)   <0.001 
Any of the above 5.3 (0.3)   7.9 (0.4)   11.0 (0.4)   <0.001 
Glycosylated hemoglobin, %c  5.29  5.27, 5.31  5.45  5.43, 5.47  5.65  5.62, 5.67 <0.001 
Total cholesterol, mg/dLc  188.3  187.3, 189.3  198.6  197.3, 200.0  199.4  198.3, 200.6 <0.001 
HDL cholesterol, mg/dL  56.5 (0.3)   51.8 (0.2)   49.8 (0.2)  <0.001 
LDL cholesterol, mg/dLc,d  107.6  106.3, 109.0  116.1  114.7, 117.5  115.1  113.5, 116.7 <0.001 
Triglycerides, mg/dLc,d  95.9  94.0, 98.0  120.7  117.8, 123.6  133.0  130.1, 136.0 <0.001 
Systolic blood pressure, mm Hg  118.4 (0.3)   122.7 (0.3)   124.9 (0.3)  <0.001 
Diastolic blood pressure, mm 
Hg 
 70.1 (0.2)   71.5 (0.2)   71.5 (0.2)  0.16 
eGFR, mL/min/1.73m2  89.2 (0.4)   86.0 (0.4)   86.3 (0.4)  0.001 
Albuminuria, % 6.4 (0.3)   9.3 (0.4)   13.0 (0.4)   <0.001 
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Alkaline phosphatase, U/Lc  59.9  59.3, 60.4  66.5  65.9, 67.1  72.9  72.1, 73.6 <0.001 
Alanine aminotransferase, U/Lc  21.7  21.5, 22.0  23.8  23.5, 24.1  23.1  22.8, 23.4 0.009 
Aspartate aminotransferase, 
U/Lc 
 23.5  23.3, 23.7  24.3  24.1, 24.5  23.6  23.4, 23.9 0.063 
γ-glutamyltransferase, U/Lc  18.7  18.4, 19.1  22.7  22.2, 23.1  25.4  24.9, 25.9 <0.001 
Total bilirubin, mg/dLc  0.75  0.74, 0.77  0.70  0.69, 0.71  0.62  0.61, 0.63 <0.001 
Blood pressure lowering 
medication, % 
          
ACEI 6.4 (0.3)   9.7 (0.4)   12.1 (0.3)   0.69 
ARB 3.4 (0.2)   4.3 (0.3)   6.6 (0.4)   0.54 
CCB 3.6 (0.2)   6.3 (0.3)   9.5 (0.4)   <0.001 
ARA 0.3 (0.1)   0.5 (0.1)   0.8 (0.1)   0.34 
β-blockers 6.4 (0.4)   9.1 (0.4)   12.3 (0.5)   0.042 
Diuretics 5.7 (0.3)   10.5 (0.5)   16.3 (0.5)   <0.001 
Others 1.9 (0.2)   3.2 (0.2)   4.0 (0.2)   0.070 
Any of the above 15.9 (0.6)   24.4 (0.6)   32.9 (0.7)   0.006 
Polytherapy 8.0 (0.4)   12.8 (0.5)   18.9 (0.5)   0.001 
Glucose lowering medication, 
% 
          
Metformin 2.2 (0.2)   3.4 (0.2)   5.3 (0.3)   0.53 
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Sulfonylureas 1.8 (0.2)   2.8 (0.2)   4.3 (0.2)   0.56 
Thiazolidinediones 1.2 (0.1)   1.3 (0.2)   1.8 (0.1)   <0.001 
Insulin 0.9 (0.1)   1.3 (0.2)   2.4 (0.2)   0.014 
Others 0.3 (0.1)   0.4 (0.1)   0.6 (0.1)   0.89 
Any of the above 3.9 (0.2)   5.8 (0.3)   9.4 (0.4)   0.32 
Polytherapy 1.8 (0.2)   2.6 (0.2)   4.1 (0.3)   0.56 
Lipid lowering medication, %           
Statin 10.7 (0.5)   13.7 (0.5)   12.8 (0.4)   <0.001 
Fibrate 0.7 (0.1)   1.5 (0.2)   1.4 (0.1)   0.58 
Bile acid sequestrant 0.1 (0.0)e   0.2 (0.1)   0.3 (0.1)   0.30 
Nicotinic acid 0.4 (0.1)   0.4 (0.1)   0.4 (0.1)   0.60 
Cholesterol adsorption 
inhibitor 
1.0 (0.1)   1.4 (0.2)   1.1 (0.1)   0.04 
Others 0.0 (0.0)e   0.0 (0.0)e   0.1 (0.0)e   0.097 
Any of the above 11.3 (0.5)   15.3 (0.6)   14.3 (0.4)   <0.001 
Polytherapy 1.5 (0.2)   1.8 (0.2)   1.7 (0.2)   0.052 
Taking aspirin, % 0.6 (0.1)   0.9 (0.1)   1.1 (0.1)   0.66 
Taking clopidogrel, % 0.9 (0.1)   1.1 (0.1)   1.5 (0.2)   0.27 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARA, aldosterone receptor antagonist; ARB, angiotensin receptor blocker; CCB, 
calcium channel blocker; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; 
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LDL, low-density lipoprotein; SE, standard error. 
aData are expressed as mean or % (SE).  For variables with skewed distribution, data are expressed as geometric mean (95% CI). 
bAdjusted for age, sex, race/ethnicity, body mass index and survey period, where appropriate.  
cData were ln-transformed before analysis due to skewed distribution. 
dData were only available in a sub-sample of subjects that had fasted for 8-24 hours (n = 3,367, 4,195, and 4,631 for subjects with CRP levels of <1.0, 
1.0-3.0 and >3.0 mg/L, respectively). 
eEstimates are unreliable due to coefficient of variation >0.3. 
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Table 3.  Prevalence of Elevated CRP and Geometric Mean CRP Levels in United States Adults, 1999-2010a 
 1999-2002 
(n = 8,074) 
2003-2006 
(n = 8,316) 
2007-2010 
(n = 10,824) 
Change, 
1999-2002 
to 
2007-2010 
P Value 
for 
12-year 
Linear 
Trend 
P Value for 
Interaction 
 % (SE)b Meanb  95% 
CIb 
% (SE)b Meanb 95% 
CIb 
% (SE)b Meanb  95% 
CIb 
   
Overall             
Elevated CRP, % 36.7 (0.8)   35.2 (0.8)**   32.0 
(0.6)*** 
  -4.7 <0.001  
CRP level, mg/L  1.92 1.82, 
2.02 
 1.87** 1.77, 
1.97 
 1.66*** 1.58, 
1.74 
-0.26 <0.001  
             
Age, years             
20-29 (n = 4,378)             
Elevated CRP, % 25.2 (1.5)   27.6 (1.4)   26.7 (1.4)   1.5 0.92 <0.001 
CRP level, mg/L  1.26 1.15, 
1.38 
 1.29 1.19, 
1.40 
 1.28** 1.16, 
1.40 
0.02 0.12 <0.001 
30-39 (n = 4,471)             
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Elevated CRP, % 32.7 (1.1)   31.1 (1.5)   30.2 (1.1)   -2.5 0.001  
CRP level, mg/L  1.64 1.52, 
1.78 
 1.61* 1.49, 
1.73 
 1.47** 1.36, 
1.59 
-0.17 <0.001  
40-49 (n = 4,863)             
Elevated CRP, % 35.5 (1.6)   37.7 (1.6)   31.6 
(1.5)** 
  -3.9 0.003  
CRP level, mg/L  1.84 1.65, 
2.06 
 2.02 1.86, 
2.21 
 1.70** 1.55, 
1.86 
-0.15 0.004  
             
50-59 (n = 3,975)             
Elevated CRP, % 43.4 (1.7)   37.1 
(2.0)*** 
  33.2 (1.4)   -10.2 <0.001  
CRP level, mg/L  2.39 2.19, 
2.61 
 2.04*** 1.86, 
2.24 
 1.76** 1.62, 
1.90 
-0.63 <0.001  
60-69 (n = 4,402)             
Elevated CRP, % 47.2 (2.0)   42.4 (1.7)*   36.6 (1.4)*   -10.6 <0.001  
CRP level, mg/L  2.75 2.57, 
2.96 
 2.54* 2.38, 
2.71 
 2.03** 1.88, 
2.20 
-0.72 <0.001  
70-79 (n = 3,145)             
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Elevated CRP, % 45.2 (1.9)   39.0 (1.8)*   38.4 (1.5)   -6.8 0.001  
CRP level, mg/L  2.78 2.57, 
3.01 
 2.29** 2.10, 
2.50 
 2.16 2.02, 
2.32 
-0.62 <0.001  
≥80 (n = 1,980)             
Elevated CRP, % 45.2 (2.4)   38.0 (1.6)   34.8 (3.0)   -10.4 0.033  
CRP level, mg/L  2.76 2.46, 
3.10 
 2.39 2.19, 
2.60 
 1.99* 1.76, 
2.24 
-0.77 0.012  
             
Sex             
Men (n = 13,605)             
Elevated CRP, % 28.7 (1.0)   28.6 (1.0)   25.8 
(0.7)** 
  -2.9 <0.001 0.16 
CRP level, mg/L  1.58 1.49, 
1.68 
 1.59 1.50, 
1.68 
 1.43*** 1.35, 
1.51 
-0.15 <0.001 0.23 
Women (n = 13,609)             
Elevated CRP, % 44.5 (1.0)   41.5 
(1.2)*** 
  38.0 
(0.7)*** 
  -6.5 <0.001  
CRP level, mg/L  2.31 2.16, 
2.48 
 2.19** 2.04, 
2.34 
 1.91*** 1.81, 
2.02 
-0.40 <0.001  
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Race/ethnicity             
Non-Hispanic White 
(n = 13,551) 
            
Elevated CRP, % 36.1 (1.0)   33.9 (1.0)**   31.1 
(0.9)** 
  -4.9 <0.001 0.007 
CRP level, mg/L  1.89 1.78, 
2.01 
 1.83** 1.72, 
1.94 
 1.62*** 1.52, 
1.73 
-0.27 <0.001 0.004 
Non-Hispanic Black 
(n = 5,210) 
            
Elevated CRP, % 42.2 (1.5)   43.4 (1.2)   41.9 (1.3)   -0.3 0.14  
CRP level, mg/L  2.26 2.02, 
2.52 
 2.34 2.17, 
2.53 
 2.13* 1.96, 
2.31 
-0.13 0.004  
Mexican American (n 
= 5,522) 
            
Elevated CRP, % 36.2 (1.3)   38.1 (1.8)   36.0 (2.1)*   -0.2 0.017  
CRP level, mg/L   1.87 1.70, 
2.05 
 2.02 1.80, 
2.27 
 2.01 1.79, 
2.25 
0.14 0.14  
Other (n = 2,931)             
Elevated CRP, % 36.3 (1.7)   32.7 (2.4)   25.6 
(1.8)*** 
  -10.7 <0.001  
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CRP level, mg/L  1.85 1.63, 
2.09 
 1.58* 1.38, 
1.81 
 1.30*** 1.18, 
1.44 
-0.54 <0.001  
             
Body mass index, 
kg/m2 
            
<25.0 (n = 8,185)             
Elevated CRP, % 20.0 (0.8)   18.0 (0.9)**   15.0 
(0.7)** 
  -5.0 <0.001 0.035 
CRP level, mg/L  1.06 0.98, 
1.14 
 1.00* 0.93, 
1.08 
 0.86*** 0.80, 
0.92 
-0.20 <0.001 0.061 
25.0-29.9 (n = 9,557)             
Elevated CRP, % 33.5 (1.1)   30.4 (0.8)**   25.3 
(1.0)** 
  -8.1 <0.001  
CRP level, mg/L  1.90 1.80, 
2.01 
 1.79* 1.71, 
1.87 
 1.49*** 1.41, 
1.58 
-0.41 <0.001  
≥30.0 (n = 9,472)             
Elevated CRP, % 59.6 (1.4)   56.7 (1.3)   53.8 (0.7)*   -5.8 0.001  
CRP level, mg/L  3.84 3.62, 
4.07 
 3.59 3.42, 
3.77 
 3.30** 3.19, 
3.42 
-0.53 <0.001  
Abbreviations: CI, confidence interval; CRP, C-reactive protein; SE, standard error. 
35 
 
*P < 0.05, **P < 0.01, and ***P < 0.001 for the 8-year linear trend compared to the previous four-year cycle (i.e. 2003-2006 vs 1999-2002 or 
2007-2010 vs 2003-2006). 
aAll P values were adjusted for age, sex (except sex-specific estimates), race/ethnicity (except race/ethnicity-specific estimates), body mass index, 
blood pressure lowering medication, glucose lowering medication, and lipid lowering medication.  CRP values were ln-transformed when assessing 
the trend in mean CRP values.  For the subgroups by age and body mass index, categorical subgroup variable, instead of the continuous level, was 
used in the adjustment model when assessing the P value for interaction. 
bData are expressed as % (SE) for elevated CRP.  For continuous CRP level, data are expressed as geometric mean (95% CI) due to skewed 
distribution.   
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Table 4.  Association of Survey Year With Elevated CRP or Geometric Mean Level in United States Adults, 1999-2010a 
Modelb Elevated CRP (>3.0 mg/L) ln CRP (mg/L) 
 Odds ratio 95% CI P Value Regression 
coefficient 
95% CI P Value 
Unadjusted  0.95 0.93, 0.97 <0.001 -0.039 -0.058, -0.021 <0.001 
1 0.92 0.90, 0.94 <0.001 -0.057 -0.071, -0.043 <0.001 
2 0.92 0.90, 0.94 <0.001 -0.053 -0.066, -0.040 <0.001 
3 0.95 0.93, 0.97 <0.001 -0.029 -0.042, -0.015 <0.001 
4 0.95 0.93, 0.98 <0.001 -0.027 -0.040, -0.013 <0.001 
5 0.95 0.93, 0.98 <0.001 -0.026 -0.040, -0.013 <0.001 
6 0.98 0.95, 1.00 0.076 -0.016 -0.030, -0.002 0.024 
Abbreviations: CI, confidence interval; CRP, C-reactive protein. 
aMultiple logistics or linear regression was used with elevated CRP or ln CRP as the dependent variable.  Data are presented as odds ratio (95% CI) 
for elevated CRP or regression coefficient (95% CI) for ln CRP level per each two-year cycle increase.  
bModel 1 was adjusted for age, sex, race/ethnicity, and body mass index; model 2, further adjusted for education, smoking and regular alcohol drinking; 
model 3, further adjusted for glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, estimated 
glomerular filtration rate, albuminuria, alkaline phosphatase, aspartate aminotransferase, and γ-glutamyltransferase; model 4, further adjusted for 
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, β-blockers, diuretics, metformin, 
thiazolidinediones, insulin, “others” category of glucose lowering medications, statins, nicotinic acid, cholesterol adsorption inhibitor, “others” 
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category of lipid lowering medications, aspirin, and clopidogrel; model 5, further adjusted for blood pressure lowering polytherapy, glucose lowering 
polytherapy, and lipid lowering polytherapy; model 6 was further adjusted for total bilirubin.
38 
 
Web Appendix 
 
MATERIALS AND METHODS 
Prescription medications 
The usage of prescription medications for lowering blood lipids, glucose, and blood pressure 
as well as aspirin and clopidogrel in the past month was assessed by questionnaires.  
Participants were asked whether they had taken or used any prescription medicine in the past 
month and showed the interviewer the medication containers and the exact name of all the 
products.  If the container was unavailable, the interviewer asked the participants to verbally 
report this information.  Lipid lowering medications were classified into statins, fibrates, 
bile acid sequestrants, nicotinic acids, cholesterol adsorption inhibitor (i.e. ezetimibe), and 
others (including probucol and other unspecified medications).  Blood pressure lowering 
medications were classified into angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers (ARBs), β-blockers, calcium channel blockers (CCBs), diuretics, 
aldosterone receptor antagonists, and others (including α-blockers, other antiadrenergic drugs, 
direct vasodilators, direct renin inhibitors and other unspecified anti-hypertensive 
medications).  Glucose lowering medications were classified into metformin, sulfonylureas, 
thiazolidinediones, insulin, and others (including α-glucosidase inhibitors, amylin analogs, 
dipeptidyl peptidase 4 inhibitors, incretin mimetics, meglitinides, and other unspecific 
anti-diabetic medications).  A participant can report the use of more than one medication, 
either as a single combination pill or several different pills.  In this case, the participant was 
only counted once for any medication use category, and once within each class of 
medications.  For example, a subject who reported the uses of “niacin/simvastatin”, 
“pravastatin”, “amlodipine, valsartan and hydrochlorothiazide”, and 
“metformin/pioglitazone” in the past month was only counted once for each of the classes, 
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nicotinic acid, statins, CCBs, ARBs, diuretics, metformin, and thiazolidinediones.  A 
participant, who took two or more different classes of medications for the same therapeutic 
use (lowering either blood lipids, glucose, or blood pressure), either as a single combination 
pill or several different pills, was defined as receiving polytherapy. 
 
Laboratory measurement 
Serum high-density lipoprotein cholesterol, total cholesterol, and triglycerides were measured 
with a Hitachi Model 704 multichannel analyzer in 1999-2004, a Roche Hitachi 717 (Roche 
Diagnostics, Indianapolis, IN) in 2005, both Roche Hitachi 717 and 912 (Roche Diagnostics, 
Indianapolis, IN) in 2006, and a Roche Modular P chemistry analyzer (Roche Diagnostics, 
Indianapolis, IN) in 2007-2010.  Low-density lipoprotein cholesterol was calculated using 
the Friedewald equation.   
 
Glycosylated hemoglobin was determined by high performance liquid chromatography using 
a Primus CLC330 or a Primus CLC385 (Primus Corporation, Kansas City, MO) in 
1999-2004, a Tosoh A1c 2.2 Plus Glycohemoglobin Analyzer (Tosoh Medics Inc, San 
Francisco, CA) in 2005-2006, and an A1c G7 HPLC Glycohemoglobin Analyzer (Tosoh 
Medics Inc, San Francisco, CA) in 2007-2010.  Serum creatinine, alkaline phosphatase, 
alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase, and total 
bilirubin levels were measured as the routine laboratory blood parameters using a Hitachi 
Model 917 multichannel analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN) in 
1999-2000, a Beckman Synchron LX20 system in 2003-2007 and a Beckman UniCel® 
DxC800 Synchron (Beckman Coulter Inc, Fullerton, CA) in 2008-2010.  In 2001-2002, 
these levels were measured using either a Hitachi Model 917 multichannel analyzer or a 
Beckman Synchron LX20.  The reported values have been adjusted by regression equations 
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to allow comparison across the two methods.  Correction for serum creatinine data in 
1999-2000 and 2005-2006 was performed according to the NHANES recommendations 
before calculating the estimated glomerular filtration rate.   
 
Urinary creatinine was determined colorimetrically by the Jaffé rate reaction in a Beckman  
Synchron CX3 Clinical Analyzer (Beckman Instruments, Brea, CA) in 1999-2006, and a 
Roche/Hitachi Modular P Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN) in 
2007-2010.  Data on urinary creatinine were adjusted using regression equations so that 
values from two different measurements could be combined and compared.  Urinary 
albumin was measured with a solid-phase fluorescent immunoassay using a Sequoia-Turner 
Digital Model 450 fluorometer (Mountain View, CA) in 1999-2010.   
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Web Table 1.  Prevalence of Elevated CRP and Geometric Mean CRP Levels in United States Adults, 1999-2010, After Excluding Subjects With 
CRP Levels >10 mg/La 
 1999-2002 
(n = 7,217) 
2003-2006 
(n = 7,419) 
2007-2010 
(n = 9,757) 
Change, 
1999-2002 
to 
2007-2010 
P Value 
for 
12-year 
Linear 
Trendb 
P Value for 
Interactionb 
 % (SE)b Meanb  95% CI % (SE)b Meanb  95% CI % (SE)b Meanb  95% CI    
Overall             
Elevated CRP, % 30.1 (0.7)   28.2 
(0.8)** 
  25.7 
(0.5)*** 
  -4.4 <0.001  
CRP level, mg/L  1.52 1.45, 
1.59 
 1.47*** 1.40, 
1.53 
 1.33*** 1.28, 
1.39 
-0.19 <0.001  
             
Age, years             
20-29 (n = 4,040)             
Elevated CRP, % 20.6 (1.5)   21.6 (1.5)   20.7 (1.3)   0.0 0.90 0.006 
CRP level, mg/L  1.06 0.98, 
1.15 
 1.04 0.96, 
1.12 
 1.02 0.93, 
1.13 
-0.04 0.10 <0.001 
30-39 (n = 4,075)             
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Elevated CRP, % 26.7 (1.1)   24.7 (1.5)*   24.5 (1.2)   -2.1 0.005  
CRP level, mg/L  1.33 1.23, 
1.44 
 1.29 1.20, 
1.39 
 1.21** 1.11, 
1.32 
-0.12 <0.001  
40-49 (n = 4,363)             
Elevated CRP, % 28.9 (1.5)   29.9 (1.5)   24.6 (1.3)   -4.3 0.014  
CRP level, mg/L  1.47 1.34, 
1.62 
 1.55 1.45, 
1.65 
 1.34* 1.24, 
1.44 
-0.14 0.006  
50-59 (n = 3,519)             
Elevated CRP, % 36.2 (1.7)   30.4 
(2.0)** 
  27.1 (1.2)   -9.2 <0.001  
CRP level, mg/L  1.87 1.74, 
2.01 
 1.62** 1.49, 
1.77 
 1.43** 1.35, 
1.51 
-0.44 <0.001  
60-69 (n = 3,837)             
Elevated CRP, % 39.1 (1.9)   34.3 (1.7)*   30.2 (1.3)   -8.9 <0.001  
CRP level, mg/L  2.08 1.96, 
2.21 
 1.94** 1.81, 
2.08 
 1.63*** 1.53, 
1.73 
-0.45 <0.001  
70-79 (n = 2,799)             
Elevated CRP, % 37.7 (2.1)   32.1 (1.9)   31.8 (1.5)   -5.9 0.007  
CRP level, mg/L  2.13 2.00, 
2.28 
 1.81*** 1.70, 
1.92 
 1.72* 1.63, 
1.82 
-0.41 <0.001  
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≥80 (n = 1,760)             
Elevated CRP, % 37.4 (2.7)   31.0 (1.5)   27.2 (3.1)   -10.3 0.024  
CRP level, mg/L  2.11 1.89, 
2.34 
 1.87 1.75, 
2.00 
 1.52* 1.35, 
1.71 
-0.59 0.002  
             
Sex             
Men (n = 12,614)             
Elevated CRP, % 24.0 (0.9)   23.8 (0.9)   21.1 (0.6)   -2.9 <0.001 0.27 
CRP level, mg/L  1.34 1.27, 
1.42 
 1.34 1.28, 
1.41 
 1.21*** 1.16, 
1.27 
-0.13 <0.001 0.36 
Women (n = 
11,779) 
            
Elevated CRP, % 36.3 (1.0)   32.7 
(1.1)*** 
  30.2 (0.7)   -6.1 <0.001  
CRP level, mg/L  1.73 1.62, 
1.85 
 1.60** 1.51, 
1.70 
 1.46*** 1.38, 
1.54 
-0.27 <0.001  
             
Race/ethnicity             
Non-Hispanic 
White (n = 12,292) 
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Elevated CRP, % 29.9 (0.9)   27.3 
(0.9)** 
  25.0 (0.8)   -4.8 <0.001 0.022 
CRP level, mg/L  1.53 1.44, 
1.62 
 1.45** 1.38, 
1.53 
 1.31*** 1.24, 
1.39 
-0.21 <0.001 0.026 
Non-Hispanic Black 
(n = 4,461) 
            
Elevated CRP, % 32.3 (1.5)   33.1 (1.1)   33.0 (1.1)   -0.7 0.38  
CRP level, mg/L  1.56 1.44, 
1.70 
 1.63 1.52, 
1.76 
 1.54* 1.45, 
1.62 
-0.03 0.009  
Mexican American 
(n = 4,962) 
            
Elevated CRP, % 30.1 (1.2)   31.1 (1.4)   29.0 (1.9)   -1.1 0.004  
CRP level, mg/L   1.50 1.38, 
1.63 
 1.57 1.44, 
1.70 
 1.61 1.45, 
1.78 
0.11 0.083  
Other (n = 2,678)             
Elevated CRP, % 29.6 (1.7)   27.5 (2.4)   20.8 (1.5)   -8.8 <0.001  
CRP level, mg/L  1.46 1.30, 
1.63 
 1.32 1.17, 
1.50 
 1.11*** 1.01, 
1.21 
-0.35 <0.001  
             
Body mass index,             
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kg/m2 
<25.0 (n = 7,714)             
Elevated CRP, % 15.9 (0.8)   13.7 (0.9)*   11.7 (0.6)   -4.2 <0.001 0.054 
CRP level, mg/L  0.91 0.85, 
0.98 
 0.85* 0.79, 
0.92 
 0.76*** 0.71, 
0.81 
-0.16 <0.001 0.12 
25.0-29.9 (n = 
8,890) 
            
Elevated CRP, % 28.4 (1.0)   25.6 
(0.8)** 
  21.3 (1.0)   -7.1 <0.001  
CRP level, mg/L  1.60 1.52, 
1.68 
 1.52* 1.47, 
1.57 
 1.31*** 1.24, 
1.38 
-0.29 <0.001  
≥30.0 (n = 7,789)             
Elevated CRP, % 51.0 (1.5)   47.4 (1.4)   44.9 (0.8)   -6.1 0.002  
CRP level, mg/L  2.79 2.67, 
2.92 
 2.58 2.46, 
2.71 
 2.42*** 2.35, 
2.48 
-0.38 <0.001  
Abbreviations: CI, confidence interval; CRP, C-reactive protein; SE, standard error. 
*P < 0.05, **P < 0.01, and ***P < 0.001 for the 8-year linear trend compared to the previous four-year cycle (i.e. 2003-2006 vs 1999-2002 or 
2007-2010 vs 2003-2006). 
aAll P values were adjusted for age, sex (except sex-specific estimates), race/ethnicity (except race/ethnicity-specific estimates), body mass index, 
blood pressure lowering medication, glucose lowering medication, and lipid lowering medication.  CRP values were ln-transformed when assessing 
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the trend in mean CRP values.  For the subgroups by age and body mass index, categorical subgroup variable, instead of the continuous level, was 
used in the adjustment model when assessing the P value for interaction. 
bData are expressed as % (SE) for elevated CRP.  For continuous CRP level, data are expressed as geometric mean (95% CI) due to skewed 
distribution.   
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Web Table 2.  Medication Use Pattern by Age and Race/ethnicity in United States Adults, 1999-2010a 
 Overall 
1999-2010 
1999-2002 2003-2006 2007-2010 Change, 1999-2002 
to 2007-2010 
P Value for 
Linear Time 
Trend 
P Value for 
Interactionb 
Any blood pressure lowering medication, % 
Age, years        
20-39 (n = 8,848) 3.7 (0.2) 3.1 (0.4) 3.7 (0.5) 4.2 (0.4) 1.1 0.21 0.14 
40-59 (n = 8,830) 23.7 (0.7) 21.2 (1.3) 24.3 (1.0) 25.4 (1.1) 4.2 0.18  
≥60 (n = 9,516) 60.1 (0.8) 53.2 (1.4) 62.1 (1.3) 63.8 (1.4) 10.5 <0.001  
Race/ethnicity        
Non-Hispanic White (n = 
13,547) 
26.7 (0.6) 22.9 (1.0) 27.5 (1.1) 29.6 (1.1) 6.6 0.001 0.62 
Non-Hispanic Black (n = 
5,200) 
28.1 (0.7) 25.1 (1.3) 28.8 (1.2) 30.1 (1.3) 5.0 0.11  
Mexican American (n = 5,520) 11.3 (0.8) 8.5 (0.8) 10.4 (1.4) 14.1 (1.4) 5.6 0.016  
Other (n = 2,927) 16.8 (0.9) 14.6 (1.2) 17.3 (2.2) 18.3 (1.1) 3.7 0.073  
        
Any glucose lowering medication, % 
Age, years        
20-39 (n = 8,848) 1.4 (0.1) 1.1 (0.2) 1.6 (0.2) 1.5 (0.2) 0.4 0.14 0.92 
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40-59 (n = 8,830) 6.3 (0.3) 5.1 (0.5) 6.3 (0.5) 7.5 (0.6) 2.4 0.021  
≥60 (n = 9,516) 14.7 (0.5) 11.9 (0.6) 14.3 (0.8) 17.2 (1.0) 5.3 0.001  
Race/ethnicity        
Non-Hispanic White (n = 
13,547) 
5.8 (0.3) 4.3 (0.4) 5.9 (0.4) 7.1 (0.6) 2.8 0.002 0.73 
Non-Hispanic Black (n = 
5,200) 
9.6 (0.4) 7.9 (0.8) 9.1 (0.6) 11.6 (0.8) 3.7 0.012  
Mexican American (n = 5,520) 6.5 (0.4) 5.2 (0.5) 6.4 (0.5) 7.6 (0.8) 2.4 0.14  
Other (n = 2,927) 7.6 (0.6) 7.1 (1.1) 7.8 (1.3) 7.8 (0.9) 0.7 0.38  
        
Any lipid lowering medication, % 
Age, years        
20-39 (n = 8,848) 1.1 (0.1) 0.7 (0.2) 0.9 (0.2) 1.6 (0.3) 0.9 0.002 0.010 
40-59 (n = 8,830) 13.1 (0.5) 9.9 (0.8) 13.4 (1.0) 15.5 (0.8) 5.6 0.001  
≥60 (n = 9,516) 35.0 (0.6) 23.4 (1.0) 35.4 (1.0) 44.1 (0.8) 20.7 <0.001  
Race/ethnicity        
Non-Hispanic White (n = 
13,547) 
15.6 (0.4) 10.9 (0.6) 15.6 (0.8) 19.9 (0.7) 9.0 <0.001 0.007 
Non-Hispanic Black (n = 
5,200) 
9.8 (0.5) 5.1 (0.5) 10.4 (0.7) 13.3 (0.8) 8.2 <0.001  
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Mexican American (n = 5,520) 6.2 (0.6) 2.8 (0.3) 5.2 (0.6) 9.7 (1.1) 6.9 <0.001  
Other (n = 2,927) 10.1 (0.7) 6.8 (1.0) 11.6 (1.6) 11.7 (0.9) 4.8 <0.001  
        
Statins, % 
Age, years        
20-39 (n = 8,848) 0.9 (0.1) 0.5 (0.1) 0.8 (0.2) 1.4 (0.3) 0.9 <0.001 0.036 
40-59 (n = 8,830) 11.7 (0.5) 8.7 (0.7) 11.8 (0.9) 14.2 (0.7) 5.5 <0.001  
≥60 (n = 9,516) 32.3 (0.5) 21.8 (0.9) 32.3 (0.9) 40.7 (0.8) 18.9 <0.001  
Race/ethnicity        
Non-Hispanic White (n = 
13,547) 
14.2 (0.4) 9.9 (0.6) 14.0 (0.7) 18.3 (0.6) 8.4 <0.001 0.004 
Non-Hispanic Black (n = 
5,200) 
9.1 (0.5) 4.5 (0.4) 9.5 (0.7) 12.6 (0.7) 8.1 <0.001  
Mexican American (n = 5,520) 5.6 (0.5) 2.4 (0.3) 4.7 (0.5) 8.7 (1.0) 6.3 <0.001  
Other (n = 2,927) 8.7 (0.6) 5.6 (0.8) 10.0 (1.4) 10.5 (0.9) 4.8 <0.001  
aData are expressed as % (standard error).  All P values were adjusted for age, sex (except sex-specific estimates), race/ethnicity (except 
race/ethnicity-specific estimates), and body mass index.   
bFor the subgroups by age, categorical subgroup variable, instead of the continuous level, was used in the adjustment model when assessing the P value 
for interaction. 
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Web Table 3.  Association of Survey Year With Elevated CRP or Geometric Mean Level in United States Adults, 1999-2010, After Excluding 
Subjects With CRP Levels >10 mg/La 
Modelb Elevated CRP (>3.0 mg/L) ln CRP (mg/L) 
 Odds ratio 95% CI P Value Regression 
coefficient 
95% CI P Value 
Unadjusted  0.95 0.93, 0.97 <0.001 -0.035 -0.051, -0.019 <0.001 
1 0.92 0.90, 0.94 <0.001 -0.051 -0.063, -0.039 <0.001 
2 0.92 0.90, 0.94 <0.001 -0.048 -0.059, -0.037 <0.001 
3 0.95 0.92, 0.97 <0.001 -0.028 -0.039, -0.016 <0.001 
4 0.95 0.93, 0.98 <0.001 -0.026 -0.037, -0.014 <0.001 
5 0.95 0.93, 0.98 <0.001 -0.026 -0.037, -0.014 <0.001 
6 0.97 0.95, 1.00 0.030 -0.018 -0.030, -0.006 0.005 
Abbreviations: CI, confidence interval; CRP, C-reactive protein. 
aMultiple logistics or linear regression was used with elevated CRP or ln CRP as the dependent variable.  Data are presented as odds ratio (95% CI) 
for elevated CRP or regression coefficient (95% CI) for ln CRP level per each two-year cycle increase.  
bModel 1 was adjusted for age, sex, race/ethnicity, and body mass index; model 2, further adjusted for education, smoking and regular alcohol drinking; 
model 3, further adjusted for glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, estimated 
glomerular filtration rate, albuminuria, alkaline phosphatase, aspartate aminotransferase, and γ-glutamyltransferase; model 4, further adjusted for 
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone receptor antagonists, β-blockers, diuretics, metformin, 
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thiazolidinediones, insulin, “others” category of glucose lowering medications, statins, nicotinic acid, cholesterol adsorption inhibitor, “others” 
category of lipid lowering medications, aspirin, and clopidogrel; model 5, further adjusted for blood pressure lowering polytherapy, glucose lowering 
polytherapy, and lipid lowering polytherapy; model 6, further adjusted for total bilirubin. 
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Web Table 4.  Alternative Regression Models for the Association of Survey Year With Elevated CRP or Geometric Mean Level in United States 
Adults, 1999-2010a 
Modelb Elevated CRP (>3.0 mg/L) ln CRP (mg/L) 
 Odds ratio 95% CI P Value Regression 
coefficient 
95% CI P Value 
1 0.95 0.93, 0.98 <0.001 -0.027 -0.041, -0.014 <0.001 
2 0.98 0.95, 1.00 0.062 -0.017 -0.031, -0.003 0.016 
Abbreviations: CI, confidence interval; CRP, C-reactive protein. 
aMultiple logistics or linear regression was used with elevated CRP or ln CRP as the dependent variable.  Data are presented as odds ratio (95% CI) 
for elevated CRP or regression coefficient (95% CI) for ln CRP level per each two-year cycle increase.   
bModel 1 was adjusted for age, sex, race/ethnicity, body mass index, education, smoking, regular alcohol drinking, glycosylated hemoglobin, total 
cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, estimated glomerular filtration rate, albuminuria, alkaline phosphatase, 
aspartate aminotransferase, γ-glutamyltransferase, any blood pressure lowering medication, any glucose lowering medication, any lipid lowering 
medication, aspirin, and clopidogrel; model 2, further adjusted for total bilirubin.
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Web Table 5.  Prevalence of Elevated CRP Levels, Geometric Mean CRP Levels, and Mean Total Bilirubin Levels in United States Adults 
According to Statin Use, 1999-2010 
 1999-2002 2003-2006 2007-2010 Change, 
1999-2002 
to 
2007-2010 
P Value 
for Linear 
Time 
Trendb 
P Value 
for 
Interactio
nb 
 % (SE)a Meana  95% CI % (SE)a Meana  95% CI % (SE)a Meana  95% CI    
Elevated CRP, %             
Without statins (n = 
23,215) 
36.5 (0.8)   34.9 (0.9)   31.8 (0.7)   -4.6 <0.001 0.11 
With statins  
(n = 3,979) 
39.4 (2.7)   36.6 (1.9)   33.1 (1.3)   -6.3 <0.001  
             
CRP level, mg/L             
Without statins (n = 
23,215) 
 1.89  1.79, 
1.99 
 1.82  1.72, 
1.93 
 1.63  1.55, 
1.72 
-0.25 <0.001 0.005 
With statins  
(n = 3,979) 
 2.33  2.02, 
2.67 
 2.21  2.06, 
2.37 
 1.80  1.65, 
1.96 
-0.53 <0.001  
             
Total bilirubin,             
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mg/dL 
Without statins (n = 
23,048) 
 0.62  0.60, 
0.63 
 0.70  0.69, 
0.72 
 0.73  0.72, 
0.74 
0.11 <0.001 0.92 
With statins  
(n = 3,946) 
 0.62  1.72, 
1.93 
 0.71  0.70, 
0.73 
 0.74  0.72, 
0.76 
0.12 <0.001  
Abbreviations: CI, confidence interval; CRP, C-reactive protein; SE, standard error. 
aData are expressed as % (SE) for elevated CRP.  For continuous CRP and total bilirubin levels, data are expressed as geometric mean (95% CI) due 
to skewed distribution. 
bCRP and total bilirubin values were ln-transformed when assessing the trend in geometric mean values.  All P values were adjusted for age, sex, 
race/ethnicity, body mass index, blood pressure lowering medication and glucose lowering medication.   
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Web Table 6.  Prevalence of Elevated CRP Levels, Geometric Mean CRP Levels, and Mean Total Bilirubin Levels in United States Adults Without 
Taking Aspirin, Clopidogrel, or any Medication for Lowering Blood Pressure, Glucose or Lipids, 1999-2010 (n = 17,495) 
 1999-2002 2003-2006 2007-2010 Change, 
1999-2002 to 
2007-2010 
P Value for 
Linear Time 
Trendb 
 % (SE)a Meana  95% CI % (SE)a Meana  95% CI % (SE)a Meana  95% CI   
Elevated CRP, % 32.3 (0.8)   31.2 (0.9)   28.4 (0.8)   -3.9 <0.001 
CRP level, mg/L  1.64 1.55, 1.75  1.60 1.51, 1.70  1.45 1.36, 
1.54 
-0.20 <0.001 
Total bilirubin, 
mg/dL 
 0.62 0.61, 0.64  0.71 0.69, 0.72  0.73 0.72, 
0.74 
0.11 <0.001 
Abbreviations: CI, confidence interval; CRP, C-reactive protein; SE, standard error. 
aData are expressed as % (SE) for elevated CRP.  For continuous CRP and total bilirubin levels, data are expressed as geometric mean (95% CI) due 
to skewed distribution. 
bCRP and total bilirubin values were ln-transformed when assessing the trend in geometric mean values.  All P values were adjusted for age, sex, 
race/ethnicity, body mass index, blood pressure lowering medication, glucose lowering medication, and lipid lowering medication.   
 
